Loading…
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control
The PI3K-Akt pathway is a major survival pathway activated in cancer. Efforts to develop targeted therapies have not been fully successful, mainly because of extensive internal intrapathway or external interpathway negative feedback loops or because of networking between pathway suppressors. The PTE...
Saved in:
Published in: | Genes & cancer 2010-12, Vol.1 (12), p.1170-1177 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3105-4caf3a2e4970d6f9dec70d6b852350845400a6a3283e0daa03f91316d5ee36ef3 |
---|---|
cites | |
container_end_page | 1177 |
container_issue | 12 |
container_start_page | 1170 |
container_title | Genes & cancer |
container_volume | 1 |
creator | Georgescu, Maria-Magdalena |
description | The PI3K-Akt pathway is a major survival pathway activated in cancer. Efforts to develop targeted therapies have not been fully successful, mainly because of extensive internal intrapathway or external interpathway negative feedback loops or because of networking between pathway suppressors. The PTEN tumor suppressor is the major brake of the pathway and a common target for inactivation in somatic cancers. This review will highlight the networking of PTEN with other inhibitors of the pathway, relevant to cancer progression. PTEN constitutes the main node of the inhibitory network, and a series of convergences at different levels in the PI3K-Akt pathway, starting from those with growth factor receptors, will be described. As PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP(3)) phosphatase, thus opposing the activity of PI3K, the concerted actions to increase the availability of PIP(3) in cancer cells, relying either on other phosphoinositide enzymes or on the intrinsic regulation of PTEN activity by other molecules, will be discussed. In particular, the synergy between PTEN and the circle of its direct interacting proteins will be brought forth in an attempt to understand both the activation of the PI3K-Akt pathway and the connections with other parallel oncogenic pathways. The understanding of the interplay between the modulators of the PI3K-Akt pathway in cancer should eventually lead to the design of therapeutic approaches with increased efficacy in the clinic. |
doi_str_mv | 10.1177/1947601911407325 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3092286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>878820636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3105-4caf3a2e4970d6f9dec70d6b852350845400a6a3283e0daa03f91316d5ee36ef3</originalsourceid><addsrcrecordid>eNpdUMFOwkAQ3RiNGOTuyfTmqTq70267FxNCUIkEScTzZmm3Umm7uNtK-HvbgESdy7zMzHtv8gi5onBLaRTdURFEHKigNIAIWXhCLrqRz4FFp0dMRY8MnPuAthCB8_Cc9FjLF0EAF0TMF-OZt2hKY73XZrOx2rkWznS9NXbt5ZU3n-CzP1zX3lzVq63aeSNT1dYUl-QsU4XTg0Pvk7eH8WL05E9fHiej4dRPkELoB4nKUDEdiAhSnolUJx1YxiHDEOIgDAAUV8hi1JAqBZgJipSnodbIdYZ9cr_X3TTLUqeJbt1VITc2L5XdSaNy-XdT5Sv5br4kgmAs5q3AzUHAms9Gu1qWuUt0UahKm8bJOIpjBhy7S9hfJtY4Z3V2dKEgu8zl_8xbyvXv746En4TxGyNSeq4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>878820636</pqid></control><display><type>article</type><title>PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control</title><source>PubMed (Medline)</source><creator>Georgescu, Maria-Magdalena</creator><creatorcontrib>Georgescu, Maria-Magdalena</creatorcontrib><description>The PI3K-Akt pathway is a major survival pathway activated in cancer. Efforts to develop targeted therapies have not been fully successful, mainly because of extensive internal intrapathway or external interpathway negative feedback loops or because of networking between pathway suppressors. The PTEN tumor suppressor is the major brake of the pathway and a common target for inactivation in somatic cancers. This review will highlight the networking of PTEN with other inhibitors of the pathway, relevant to cancer progression. PTEN constitutes the main node of the inhibitory network, and a series of convergences at different levels in the PI3K-Akt pathway, starting from those with growth factor receptors, will be described. As PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP(3)) phosphatase, thus opposing the activity of PI3K, the concerted actions to increase the availability of PIP(3) in cancer cells, relying either on other phosphoinositide enzymes or on the intrinsic regulation of PTEN activity by other molecules, will be discussed. In particular, the synergy between PTEN and the circle of its direct interacting proteins will be brought forth in an attempt to understand both the activation of the PI3K-Akt pathway and the connections with other parallel oncogenic pathways. The understanding of the interplay between the modulators of the PI3K-Akt pathway in cancer should eventually lead to the design of therapeutic approaches with increased efficacy in the clinic.</description><identifier>ISSN: 1947-6019</identifier><identifier>EISSN: 1947-6027</identifier><identifier>DOI: 10.1177/1947601911407325</identifier><identifier>PMID: 21779440</identifier><language>eng</language><publisher>United States: SAGE Publications</publisher><ispartof>Genes & cancer, 2010-12, Vol.1 (12), p.1170-1177</ispartof><rights>The Author(s) 2011 2011 The Author(s)</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3105-4caf3a2e4970d6f9dec70d6b852350845400a6a3283e0daa03f91316d5ee36ef3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092286/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092286/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21779440$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Georgescu, Maria-Magdalena</creatorcontrib><title>PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control</title><title>Genes & cancer</title><addtitle>Genes Cancer</addtitle><description>The PI3K-Akt pathway is a major survival pathway activated in cancer. Efforts to develop targeted therapies have not been fully successful, mainly because of extensive internal intrapathway or external interpathway negative feedback loops or because of networking between pathway suppressors. The PTEN tumor suppressor is the major brake of the pathway and a common target for inactivation in somatic cancers. This review will highlight the networking of PTEN with other inhibitors of the pathway, relevant to cancer progression. PTEN constitutes the main node of the inhibitory network, and a series of convergences at different levels in the PI3K-Akt pathway, starting from those with growth factor receptors, will be described. As PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP(3)) phosphatase, thus opposing the activity of PI3K, the concerted actions to increase the availability of PIP(3) in cancer cells, relying either on other phosphoinositide enzymes or on the intrinsic regulation of PTEN activity by other molecules, will be discussed. In particular, the synergy between PTEN and the circle of its direct interacting proteins will be brought forth in an attempt to understand both the activation of the PI3K-Akt pathway and the connections with other parallel oncogenic pathways. The understanding of the interplay between the modulators of the PI3K-Akt pathway in cancer should eventually lead to the design of therapeutic approaches with increased efficacy in the clinic.</description><issn>1947-6019</issn><issn>1947-6027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNpdUMFOwkAQ3RiNGOTuyfTmqTq70267FxNCUIkEScTzZmm3Umm7uNtK-HvbgESdy7zMzHtv8gi5onBLaRTdURFEHKigNIAIWXhCLrqRz4FFp0dMRY8MnPuAthCB8_Cc9FjLF0EAF0TMF-OZt2hKY73XZrOx2rkWznS9NXbt5ZU3n-CzP1zX3lzVq63aeSNT1dYUl-QsU4XTg0Pvk7eH8WL05E9fHiej4dRPkELoB4nKUDEdiAhSnolUJx1YxiHDEOIgDAAUV8hi1JAqBZgJipSnodbIdYZ9cr_X3TTLUqeJbt1VITc2L5XdSaNy-XdT5Sv5br4kgmAs5q3AzUHAms9Gu1qWuUt0UahKm8bJOIpjBhy7S9hfJtY4Z3V2dKEgu8zl_8xbyvXv746En4TxGyNSeq4</recordid><startdate>20101201</startdate><enddate>20101201</enddate><creator>Georgescu, Maria-Magdalena</creator><general>SAGE Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20101201</creationdate><title>PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control</title><author>Georgescu, Maria-Magdalena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3105-4caf3a2e4970d6f9dec70d6b852350845400a6a3283e0daa03f91316d5ee36ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Georgescu, Maria-Magdalena</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Genes & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Georgescu, Maria-Magdalena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control</atitle><jtitle>Genes & cancer</jtitle><addtitle>Genes Cancer</addtitle><date>2010-12-01</date><risdate>2010</risdate><volume>1</volume><issue>12</issue><spage>1170</spage><epage>1177</epage><pages>1170-1177</pages><issn>1947-6019</issn><eissn>1947-6027</eissn><abstract>The PI3K-Akt pathway is a major survival pathway activated in cancer. Efforts to develop targeted therapies have not been fully successful, mainly because of extensive internal intrapathway or external interpathway negative feedback loops or because of networking between pathway suppressors. The PTEN tumor suppressor is the major brake of the pathway and a common target for inactivation in somatic cancers. This review will highlight the networking of PTEN with other inhibitors of the pathway, relevant to cancer progression. PTEN constitutes the main node of the inhibitory network, and a series of convergences at different levels in the PI3K-Akt pathway, starting from those with growth factor receptors, will be described. As PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP(3)) phosphatase, thus opposing the activity of PI3K, the concerted actions to increase the availability of PIP(3) in cancer cells, relying either on other phosphoinositide enzymes or on the intrinsic regulation of PTEN activity by other molecules, will be discussed. In particular, the synergy between PTEN and the circle of its direct interacting proteins will be brought forth in an attempt to understand both the activation of the PI3K-Akt pathway and the connections with other parallel oncogenic pathways. The understanding of the interplay between the modulators of the PI3K-Akt pathway in cancer should eventually lead to the design of therapeutic approaches with increased efficacy in the clinic.</abstract><cop>United States</cop><pub>SAGE Publications</pub><pmid>21779440</pmid><doi>10.1177/1947601911407325</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1947-6019 |
ispartof | Genes & cancer, 2010-12, Vol.1 (12), p.1170-1177 |
issn | 1947-6019 1947-6027 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3092286 |
source | PubMed (Medline) |
title | PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T19%3A07%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PTEN%20Tumor%20Suppressor%20Network%20in%20PI3K-Akt%20Pathway%20Control&rft.jtitle=Genes%20&%20cancer&rft.au=Georgescu,%20Maria-Magdalena&rft.date=2010-12-01&rft.volume=1&rft.issue=12&rft.spage=1170&rft.epage=1177&rft.pages=1170-1177&rft.issn=1947-6019&rft.eissn=1947-6027&rft_id=info:doi/10.1177/1947601911407325&rft_dat=%3Cproquest_pubme%3E878820636%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3105-4caf3a2e4970d6f9dec70d6b852350845400a6a3283e0daa03f91316d5ee36ef3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=878820636&rft_id=info:pmid/21779440&rfr_iscdi=true |